Changeflow GovPing Pharma & Drug Safety SYK Patent: Neurodegenerative Disease Treatment...
Routine Notice Added Final

SYK Patent: Neurodegenerative Disease Treatment Methods

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260097056A1 disclosing SYK activators and inhibitors for treating neurodegenerative diseases. The application covers specific compounds and methods for disease treatment. Inventors: John R. Lukens, Hannah Elizabeth Ennerfelt, Elizabeth Frost. Filed September 20, 2023.

What changed

USPTO published patent application US20260097056A1 covering methods and compositions using SYK (Spleen Tyrosine Kinase) activators and inhibitors for treating neurodegenerative diseases. The application includes claims to various compound classes and treatment protocols.

Pharmaceutical companies and biotech firms researching neurodegeneration or SYK-targeting therapies may use this published application as prior art in freedom-to-operate analyses and research planning.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES

Application US20260097056A1 Kind: A1 Apr 09, 2026

Inventors

John R. Lukens, Hannah Elzabeth Ennerfelt, Elizabeth Frost

Abstract

Provided herein are methods to treat neurodegenerative disease.

CPC Classifications

A61K 31/702 A61K 31/05 A61K 31/36 A61K 31/437 A61K 31/4985 A61K 31/501 A61K 31/506 A61K 31/519 A61K 31/5377 A61K 31/5383 A61K 31/675 A61P 25/28

Filing Date

2023-09-20

Application No.

19112913

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097056A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug development Patent filing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!